Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | F7 | P08709 | 3/20 | 0.65 |
| ▸ | F3 | P13726 | 3/20 | 0.65 |
| ▸ | PPARG | P37231 | 3/20 | 0.65 |
| ▸ | PPARD | Q03181 | 2/20 | 0.65 |
| ▸ | PPARA | Q07869 | 2/20 | 0.65 |
| ▸ | FABP3 | P05413 | 2/20 | 0.65 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.65 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.65 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.65 |
| ▸ | FABP4 | P15090 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6477506 | 1.00 | TRPV1 (0.70) | TRPV1ALDH1A1KDM4EF7F3 | |
| SCHEMBL6472470 | 1.00 | TRPV1 (0.70) | TRPV1ALDH1A1KDM4EF7F3 | |
| SCHEMBL6473134 | 1.00 | TRPV1 (0.70) | TRPV1ALDH1A1KDM4EF7F3 | |
| SCHEMBL220462 | 1.00 | TRPV1 (0.70) | TRPV1ALDH1A1KDM4EF7F3 | |
| SCHEMBL20503612 | 1.00 | TRPV1 (0.70) | TRPV1ALDH1A1KDM4EF7F3 | |
| SCHEMBL24283496 | 1.00 | TRPV1 (0.70) | TRPV1ALDH1A1KDM4EF7F3 | |
| SCHEMBL6476959 | 1.00 | TRPV1 (0.70) | TRPV1ALDH1A1KDM4EF7F3 | |
| SCHEMBL59342 | 1.00 | TRPV1 (0.70) | TRPV1ALDH1A1KDM4EF7F3 | |
| SCHEMBL6477509 | 1.00 | TRPV1 (0.70) | TRPV1ALDH1A1KDM4EF7F3 | |
| SCHEMBL18035471 | 1.00 | TRPV1 (0.70) | TRPV1ALDH1A1KDM4EF7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018123-A1 | COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-01-18 | — | — | US | disclosed |
| CN-109715607-B | Compounds that inhibit the formation of the C-MYC/MAX/DNA complex | 国立癌症中心 | 2022-07-12 | — | — | CN | disclosed |
| EP-3525788-A1 | TREATMENT OF SYNUCLEINOPATHIES | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (DE) | 2019-08-21 | — | — | EP | disclosed |
| CN-109846884-A | With TOR kinase inhibitor for treating cancer | 西格诺药品有限公司 | 2019-06-07 | — | — | CN | disclosed |
| CN-109715159-A | Anticancer medicine composition | 国立癌症中心 | 2019-05-03 | — | — | CN | disclosed |
| CN-105358177-B | Combination therapy comprising TOR kinase inhibitor and IMID compound for treating cancer | 西格诺药品有限公司 | 2018-11-23 | — | — | CN | disclosed |
| WO-2018069312-A1 | TREATMENT OF SYNUCLEINOPATHIES | DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E. V. (DZNE) (DE) | 2018-04-19 | — | — | WO | disclosed |
| EP-3178816-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUND AND ITS USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2017-06-14 | — | — | EP | disclosed |
| EP-3103800-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUND AND ITS USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-2654751-B1 | PHOSPHORUS-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | PURDUE PHARMA LP (US) | 2016-11-23 | — | — | EP | disclosed |
| WO-2003099221-A2 | METHODS FOR USING JNK INHIBITORS FOR TREATING OR PREVENTING DISEASE-RELATED WASTING | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| US-5753704-A | Therapeutic compositions comprising unsaturated dioic acids or derivatives thereof | UNICHEMA CHEMIE B.V. (NL) | 1998-05-19 | — | — | US | disclosed |
| EP-0662946-B1 | UNSATURATED ALIPHATIC DICARBOXYLIC ACIDS | UNICHEMA CHEMIE BV (NL) | 1998-03-11 | — | — | EP | disclosed |
| US-5705144-A | SKIN LIGHTENING COMPOSITION AND RADIATION RESISTANCE | UNILEVER PATENT HOLDINGS B.V. (NL) | 1998-01-06 | — | — | US | disclosed |
| EP-0662818-B1 | COSMETIC COMPOSITION CONTAINING RETINOL | UNILEVER PLC (GB) | 1997-11-05 | — | — | EP | disclosed |
| EP-0662946-A1 | UNSATURATED ALIPHATIC DICARBOXYLIC ACIDS | UNICHEMA CHEMIE B.V. (NL) | 1995-07-19 | — | — | EP | disclosed |
| EP-0662818-A1 | COSMETIC COMPOSITION CONTAINING RETINOL | UNILEVER PLC (GB) | 1995-07-19 | — | — | EP | disclosed |
| WO-1994007462-A1 | COSMETIC COMPOSITION CONTAINING RETINOL | UNILEVER PLC (GB) | 1994-04-14 | — | — | WO | disclosed |
| WO-1994007837-A1 | UNSATURATED ALIPHATIC DICARBOXYLIC ACIDS | UNICHEMA CHEMIE B.V. (NL) | 1994-04-14 | — | — | WO | disclosed |
| WO-1991013872-A1 | THERAPEUTICALLY USEFUL HETEROCYCLIC INDOLE COMPOUNDS | THE UPJOHN COMPANY (US) | 1991-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018123-A1 | COMPOUND FOR INHIBITING OR DISINTEGRATING ANDROGEN RECEPTOR, AND PHARMACEUTICAL USE THEREOF | AR, NR5A1, SHBG | TRPV1 558/4885ALDH1A1 2825/4885KDM4E 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.